A. Vaknin

Alemtuzumab mediates T-regulatory response via macrophagal CD23.

N. Bosak, I. Lotan, A. Shifrin, 2020 .

Titin antibodies in “seronegative” myasthenia gravis — A new role for an old antigen

N. Gilhus, K. Kleopa, R. Mantegazza, 2016, Journal of Neuroimmunology.

A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.

K. Kleopa, T. Stojkovic, R. Mantegazza, 2014, Journal of autoimmunity.

MuSK autoantibodies in myasthenia gravis detected by cell based assay — A multinational study

K. Kleopa, R. Mantegazza, T. Sharshar, 2015, Journal of Neuroimmunology.

Neurological abnormalities associated with celiac disease

R. Eliakim, Z. Ackerman, I. Steiner, 2004, Journal of Neurology.

Alemtuzumab mediates the CD39+ T‐regulatory cell response via CD23+ macrophages

N. Bosak, I. Lotan, M. Hellmann, 2020, Immunology and cell biology.

Functional MRI as a tool for assessing chiasmal visual defect in a patient with neuromyelitis optica

N. Raz, S. Chokron, T. Ben-Hur, 2010, Journal of Neurology, Neurosurgery & Psychiatry.